Exact Sciences Co. (NASDAQ:EXAS) EVP Brian Baranick Sells 929 Shares

Exact Sciences Co. (NASDAQ:EXAS) EVP Brian Baranick sold 929 shares of Exact Sciences stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the completion of the transaction, the executive vice president now owns 12,758 shares in the company, valued at $893,060. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Brian Baranick also recently made the following trade(s):

• On Wednesday, September 18th, Brian Baranick sold 929 shares of Exact Sciences stock. The shares were sold at an average price of $70.00, for a total value of $65,030.00.

Exact Sciences Stock Down 0.1 %

EXAS stock traded down $0.05 during trading hours on Wednesday, hitting $68.52. The company’s stock had a trading volume of 1,338,628 shares, compared to its average volume of 2,623,867. The company has a quick ratio of 1.98, a current ratio of 2.17 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $12.64 billion, a PE ratio of -51.95 and a beta of 1.27. The stock has a 50 day moving average price of $62.21 and a two-hundred day moving average price of $56.45. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.28. The firm had revenue of $699.26 million during the quarter, compared to analyst estimates of $690.02 million. Exact Sciences had a negative net margin of 6.70% and a negative return on equity of 4.97%. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.45) earnings per share. On average, equities research analysts expect that Exact Sciences Co. will post -0.87 earnings per share for the current year.

Analyst Ratings Changes

EXAS has been the subject of a number of analyst reports. Evercore ISI upped their price objective on shares of Exact Sciences from $72.00 to $80.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus decreased their price objective on shares of Exact Sciences from $100.00 to $82.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Canaccord Genuity Group restated a “buy” rating and issued a $75.00 target price on shares of Exact Sciences in a report on Friday, September 13th. The Goldman Sachs Group decreased their target price on Exact Sciences from $88.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, July 17th. Finally, Wells Fargo & Company initiated coverage on Exact Sciences in a research report on Tuesday, August 27th. They set an “overweight” rating and a $75.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, Exact Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $78.38.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Exact Sciences by 65.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 452 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 179 shares in the last quarter. Able Wealth Management LLC bought a new position in Exact Sciences during the 4th quarter valued at about $45,000. Itau Unibanco Holding S.A. acquired a new position in Exact Sciences in the second quarter valued at about $29,000. EverSource Wealth Advisors LLC grew its stake in Exact Sciences by 92.4% during the first quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after buying an additional 340 shares during the last quarter. Finally, Fortitude Family Office LLC acquired a new stake in shares of Exact Sciences during the first quarter worth approximately $55,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.